George Scangos Net Worth

The estimated Net Worth of George A Scangos is at least 64 百万$ dollars as of 22 February 2024. George Scangos owns over 27,750 units of Vir Biotechnology Inc stock worth over 884,704$ and over the last 22 years he sold VIR stock worth over 59,124,408$. In addition, he makes 3,944,610$ as President、 Chief Executive Officer、 Director at Vir Biotechnology Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

George Scangos VIR stock SEC Form 4 insiders trading

George has made over 291 trades of the Vir Biotechnology Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 27,750 units of VIR stock worth 307,193$ on 22 February 2024.

The largest trade he's ever made was exercising 358,332 units of Vir Biotechnology Inc stock on 5 December 2016 worth over 3,221,405$. On average, George trades about 8,184 units every 21 days since 2003. As of 22 February 2024 he still owns at least 112,989 units of Vir Biotechnology Inc stock.

You can see the complete history of George Scangos stock trades at the bottom of the page.

George Scangos biography

Dr. George A. Scangos Ph.D. serves as President, Chief Executive Officer, Director of the Company. From July 2010 to December 2016, Dr. Scangos served as Chief Executive Officer and as a member of the board of directors of Biogen Inc. (“Biogen”), a publicly traded biopharmaceutical company focused on the treatment of serious diseases. From October 1996 to July 2010, Dr. Scangos served as President and Chief Executive Officer of Exelixis, Inc., a drug discovery and development company. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer Biotechnology’s biological products. Before joining Bayer Biotechnology in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University. Dr. Scangos has served as a member of the board of directors of various publicly traded companies, including: Exelixis, Inc., since 1996; Agilent Technologies, Inc., a life sciences, diagnostics and applied chemical analysis company, since 2014; and Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2003 to 2010. Dr. Scangos served as Chair of PhRMA in 2016, and as the Chair of the California Healthcare Institute in 2010. He was a member of the board of directors of the Global Alliance for TB Drug Development from 2006 until 2010. Dr. Scangos currently serves on the Board of Trustees of Cornell University and the Board of Overseers of the University of California, San Francisco. Dr. Scangos received his B.A. in Biology from Cornell University and a Ph.D. in Microbiology from the University of Massachusetts.

What is the salary of George Scangos?

As the President、 Chief Executive Officer、 Director of Vir Biotechnology Inc, the total compensation of George Scangos at Vir Biotechnology Inc is 3,944,610$. There are no executives at Vir Biotechnology Inc getting paid more.

How old is George Scangos?

George Scangos is 71, he's been the President、 Chief Executive Officer、 Director of Vir Biotechnology Inc since 2017. There are 3 older and 19 younger executives at Vir Biotechnology Inc. The oldest executive at Vir Biotechnology Inc is Phillip Sharp, 75, who is the Independent Director.

What's George Scangos's mailing address?

George's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.

Insiders trading at Vir Biotechnology Inc

Over the last 5 years, insiders at Vir Biotechnology Inc have traded over 197,171,926$ worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth 139,246,875$ . The most active insiders traders include Norbert W Bischofberger、Endurance (Cayman) Ltd Sb I...、Kristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of 478,115$. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth 95,082$.

What does Vir Biotechnology Inc do?

vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.

Complete history of George Scangos stock trades at Biogen Inc、Exelixis Inc、Voyager Therapeutics Inc、Agilent Technologies、Vir Biotechnology Inc

Vir Biotechnology Inc executives and stock owners

Vir Biotechnology Inc executives and other stock owners filed with the SEC include:

• George Scangos,
  President, Chief Executive Officer, Director
• Howard Horn,
  Chief Financial Officer, Secretary
• Herbert Virgin,
  Executive Vice President of Research and Chief Scientific Officer
• Vicki Sato,
  Independent Chairman of the Board
• Dr. Herbert W. Virgin IV, M.D., Ph.D.,
  Exec. VP of Research & Chief Scientific Officer
• Dr. Herbert W. Virgin IV,
  Exec. VP of Research & Chief Scientific Officer
• Dr. George A. Scangos Ph.D.,
  Pres, CEO & Director
• Dr. Ann M. Hanly Ph.D.,
  Exec. VP & Chief Technology Officer
• Phil Pang,
  Chief Medical Officer
• Dr. George A. Scangos,
  Pres, CEO & Director
• Dr. Phillip Pang M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Steven J. Rice,
  Chief Admin. Officer
• Saira Ramasastry,
  Independent Director
• Robert Perez,
  Independent Director
• Phillip Sharp,
  Independent Director
• Dr. Klaus Frueh,
  Co-Founder & Scientific Advisor
• Robert More,
  Independent Director
• Dipchand Nishar,
  Independent Director
• Robert Nelsen,
  Independent Director
• Elliott Sigal,
  Independent Director
• Janet Napolitano,
  Director
• Michael Kamarck,
  Chief Technology Officer
• Jay Parrish,
  Chief Business Officer
• Johanna Friedl-Naderer,
  Exec. VP & COO
• Irene Pleasure J.D., Ph.D.,
  Sr. VP & Gen. Counsel
• Heather Rowe Armstrong,
  VP of Investor Relations
• Dr. Aine M. Hanly Ph.D.,
  Chief Technology Officer
• Dr. Louis J. Picker M.D.,
  Co-Founder & Scientific Advisor
• Dr. Klaus Frueh Ph.D.,
  Co-Founder & Scientific Advisor
• Dr. Neera Dahiya Ravindran M.D., MBA,
  VP and Head of Investor Relations & Strategic Communications
• Dr. Louis J. Picker,
  Co-Founder & Scientific Advisor
• Dr. Lawrence Corey,
  Co-Founder & Scientific Advisor
• Permanent Fund Corp Alaska,
  
• & Melinda Gates Foundation ...,
  
• Johanna Friedl Naderer,
  EVP & Chief Operating Officer
• Steven J. Rice,
  Chief Administrative Officer
• Venture Partners Ix, Llcarc...,
  
• Endurance (Cayman) Ltd Sb I...,
  
• Dhabi Investment Authority ...,
  
• Holdings (Private) Ltd Full...,
  
• Program Ii (Co Invest Holdi...,
  
• Mark Eisner,
  EVP and Chief Medical Officer
• Klaus Frueh,
  Director
• Venture Partners Ix, Llcarc...,
  
• Kristina Burow,
  Director
• Jeffrey S. Hatfield,
  Director
• Norbert W Bischofberger,
  Director
• Ramy Farid,
  Director
• Sung Lee,
  EVP & Chief Financial Officer
• Ann M. Hanly,
  EVP & Chief Technology Officer
• Backer Marianne De,
  Chief Executive Officer